Middlemiss DN - Search Results

1

In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.

Watson JM, Hunter AJ, Brown AM, Middlemiss DN. Watson JM, et al. Among authors: middlemiss dn. Eur J Pharmacol. 1999 Apr 1;370(1):69-77. doi: 10.1016/s0014-2999(99)00081-3. Eur J Pharmacol. 1999. PMID: 10323282

2

GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors.

Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN. Watson JM, et al. Among authors: middlemiss dn. Eur J Pharmacol. 1996 Oct 31;314(3):365-72. doi: 10.1016/s0014-2999(96)00579-1. Eur J Pharmacol. 1996. PMID: 8957260

3

Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.

Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, Brown AM. Thomas DR, et al. Among authors: middlemiss dn. Br J Pharmacol. 1998 Jul;124(6):1300-6. doi: 10.1038/sj.bjp.0701946. Br J Pharmacol. 1998. PMID: 9720804 Free PMC article.

4

Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.

Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM. Watson J, et al. Among authors: middlemiss dn. Br J Pharmacol. 1998 Dec;125(7):1413-20. doi: 10.1038/sj.bjp.0702201. Br J Pharmacol. 1998. PMID: 9884068 Free PMC article.

5

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.

Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN. Wood MD, et al. Among authors: middlemiss dn. Br J Pharmacol. 1999 Apr;126(7):1620-4. doi: 10.1038/sj.bjp.0702463. Br J Pharmacol. 1999. PMID: 10323594 Free PMC article.

6

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor.

Middlemiss DN, Göthert M, Schlicker E, Scott CM, Selkirk JV, Watson J, Gaster LM, Wyman P, Riley G, Price GW. Middlemiss DN, et al. Eur J Pharmacol. 1999 Jun 30;375(1-3):359-65. doi: 10.1016/s0014-2999(99)00262-9. Eur J Pharmacol. 1999. PMID: 10443589

7

5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors.

Thomas DR, Middlemiss DN, Taylor SG, Nelson P, Brown AM. Thomas DR, et al. Among authors: middlemiss dn. Br J Pharmacol. 1999 Sep;128(1):158-64. doi: 10.1038/sj.bjp.0702759. Br J Pharmacol. 1999. PMID: 10498847 Free PMC article.

8

Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H, Riley G, Gager T, Stean T, Upton N, Clarke SE, Brown AM, Middlemiss DN. Routledge C, et al. Among authors: middlemiss dn. Br J Pharmacol. 2000 Aug;130(7):1606-12. doi: 10.1038/sj.bjp.0703457. Br J Pharmacol. 2000. PMID: 10928964 Free PMC article.

9

Serotonergic targets in depression.

Middlemiss DN, Price GW, Watson JM. Middlemiss DN, et al. Curr Opin Pharmacol. 2002 Feb;2(1):18-22. doi: 10.1016/s1471-4892(01)00116-3. Curr Opin Pharmacol. 2002. PMID: 11786304 Review.

10

SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.

Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP. Kennett GA, et al. Among authors: middlemiss dn. Neuropharmacology. 1997 Apr-May;36(4-5):609-20. doi: 10.1016/s0028-3908(97)00038-5. Neuropharmacology. 1997. PMID: 9225286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters